Suda Pharmaceuticals Ltdの利益マージン
Suda Pharmaceuticals Ltdの利益マージンは何ですか。
Suda Pharmaceuticals Ltdの利益マージンは-448.72%です。
利益マージンの定義は何ですか。
利益マージンは、収益性の尺度であり、収益の割合として純利益を求めることによって計算されます。
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
ASXのセクタHealth Careにおける利益マージンの企業と比べるSuda Pharmaceuticals Ltd
Suda Pharmaceuticals Ltdは何をしますか。
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Suda Pharmaceuticals Ltdと類似の利益マージン
- China Xiangtai Food Coの利益マージンは-450.80%です。
- City of London plcの利益マージンは-450.49%です。
- Food Wiseの利益マージンは-450.19%です。
- Skin Elementsの利益マージンは-449.52%です。
- Taiga Motorsの利益マージンは-449.47%です。
- Liquidia Corpの利益マージンは-448.89%です。
- Suda Pharmaceuticals Ltdの利益マージンは-448.72%です。
- Auroch Mineralsの利益マージンは-445.47%です。
- Classic Mineralsの利益マージンは-444.97%です。
- Better Plant Sciencesの利益マージンは-444.87%です。
- Coho Collective Kitchensの利益マージンは-444.59%です。
- Peppermint Innovationの利益マージンは-443.81%です。
- Future Worldの利益マージンは-440.82%です。